TRR.RTR.RRT {replicateBE} | R Documentation |
Reference Datasets for TRR|RTR|RRT (partial) Replicate Designs
Description
Datasets from the public domain or simulated to be evaluated by method.A()
, method.B()
, or ABE()
.
Format
Reference Dataset 02
24 subjects.
Balanced (eight subjects in each of the three sequences) and complete (no missing data). No outliers.
A data frame with 72 observations on the following 6 variables:- rds02
-
subject
a factor with 24 levels: 1, 2, ..., 24 period
a factor with 3 levels: 1, 2, 3 sequence
a factor with 3 levels: TRR, RTR, RRT treatment
a factor with 2 levels: T, R PK
a numeric vector of pharmacokinetic responses acceptable for reference-scaling (generally Cmax) logPK
a numeric vector of the natural logarithms of PK
In the source evaluated by SAS v9.1 for ABEL. Reported results:
- SAS Proc GLM
-
CVwR
11.2% PE
102.26% (Method A and B) 90% CI
97.32% – 107.46% (Method A and B)
Reference Dataset 04
Data set of Table II given by Patterson & Jones. 51 subjects.
Balanced (17 subjects in each of the three sequences) and complete. No outliers.
A data frame with 153 observations on the following 5 variables:- rds04
-
subject
a factor with 51 levels: 1, 2, ..., 56 period
a factor with 3 levels: 1, 2, 3 sequence
a factor with 3 levels: TRR, RTR, RRT treatment
a factor with 2 levels: T, R PK
a numeric vector of pharmacokinetic responses (here Cmax)
In the source evaluated by SAS with the FDA’s mixed effects model (termed ‘Method C’ by the EMA; not compatible with the guideline). Reported results:
- SAS Proc MIXED
-
CVwR
61% PE
137% 90% CI
119% – 159%
Reference Dataset 07
Simulated with CVwT = CVwR = 35%, GMR 0.90. 360 subjects.
Balanced (120 subjects in each of the three sequences) and complete. No outliers.
A data frame with 1,080 observations on the following 5 variables:- rds07
-
subject
a factor with 360 levels: 1, 2, ..., 360 period
a factor with 3 levels: 1, 2, 3 sequence
a factor with 3 levels: TRR, RTR, RRT treatment
a factor with 2 levels: T, R PK
a numeric vector of pharmacokinetic responses (generally Cmax)
Reference Dataset 30
Simulated with heteroscedasticity (CVwT = 14%, CVwR = 28%, CVbT = 28%, CVbR = 56%), GMR = 0.90. 12 subjects. 14 subjects.
Imbalanced (six subjects in sequence TRR, five in RTR, and three RRT) and incomplete (two missings in sequences TRR and RTR and three in sequence RRT). Missings / period: 0/1, 0/2, 7/3. No outliers.
A data frame with 35 observations on the following 5 variables:- rds30
-
subject
a factor with 14 levels: 1, 2, ..., 39 period
a factor with 3 levels: 1, 2, 3 sequence
a factor with 3 levels: TRR, RTR, RRT treatment
a factor with 2 levels: T, R PK
a numeric vector of pharmacokinetic responses (generally Cmax)
Details
Dataset | N | CVwR (%) | Evaluation |
rds02 | 24 | <30 | method.A() , method.B() , ABE() |
rds04 | 51 | >30 | method.A() , method.B() |
rds07 | 360 | >30 | method.A() , method.B() |
rds30 | 14 | <30 | method.A() , method.B() , ABE()
|
Note
In software sequences and treatments are ranked in lexical order. Hence, executing str()
or summary()
will show sequence
as "RRT", "RTR", "TRR"
and treatment
as "R", "T"
. In BE – by convention – sequences are ordered with T
first. The package follows this convention.
Author(s)
Helmut Schütz (R-code for simulations by Detlew Labes)
Source
Dataset | Origin | Description |
rds02 | EMA | Annex III. |
rds04 | Patterson & Jones | Cmax data of Table II. |
rds07 | R | Large simulated data set with homoscedasticity. |
rds30 | R | Simulated with heteroscedasticity; imbalanced and incomplete. |
References
European Medicines Agency. London, 21 September 2016. Annex I, Annex III.
Patterson SD, Jones B. Viewpoint: observations on scaled average bioequivalence. Pharm Stat. 2012; 11(1): 1–7. doi:10.1002/pst.498
Examples
str(rds02)
row <- c(10:12, 1:3, 16:18)
rds02[row, ]
summary(rds02[2:6])